These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21939138)

  • 1. [Development of diabetes requires preventive action. "It is our goal to cure diabetes" (interview by Wolfgang van den Bergh, Wolfgang Geissel and Helmut Laschet)].
    Schneidewind G; Oldigs J
    MMW Fortschr Med; 2011 Aug; 153(32-34):12. PubMed ID: 21939138
    [No Abstract]   [Full Text] [Related]  

  • 2. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
    [No Abstract]   [Full Text] [Related]  

  • 3. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
    Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582
    [No Abstract]   [Full Text] [Related]  

  • 4. [MSD executive calls for more transparency and expertise. 9 out of 10 innovations fail due to a too brief value assessment (interview by Wolfgang van den Bergh, Dirk Einecke and Cornelius Heyer)].
    Quodt H
    MMW Fortschr Med; 2011 Jan; 153(4):10. PubMed ID: 22165606
    [No Abstract]   [Full Text] [Related]  

  • 5. [The goal is: fewer side effects, better compliance (interview by Wolfgang van den Bergh, Michael Hubert and Helmut Laschet)].
    Martens K
    MMW Fortschr Med; 2011 Sep; 153(36):10. PubMed ID: 21936091
    [No Abstract]   [Full Text] [Related]  

  • 6. [Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits].
    MMW Fortschr Med; 2008 Dec; 150(49-50):56-7. PubMed ID: 19133372
    [No Abstract]   [Full Text] [Related]  

  • 7. [New developments also in general medicine. GSK relies on research as well as transparent collaboration with physicians (interview by Dirk Einecke, Wolfgang van den Bergh, Peter Overbeck and Cornelius Heyer)].
    Marshall CG; Strohmeyer T
    MMW Fortschr Med; 2011 May; 153(21):10-1. PubMed ID: 21739676
    [No Abstract]   [Full Text] [Related]  

  • 8. [New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
    Nawroth P
    Dtsch Med Wochenschr; 2010 May; 135(18):923. PubMed ID: 20425679
    [No Abstract]   [Full Text] [Related]  

  • 9. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycemic control and preventive care measures of indigent diabetes patients within a pharmacist-managed insulin titration program vs standard care.
    Salvo MC; Brooks AM
    Ann Pharmacother; 2012 Jan; 46(1):29-34. PubMed ID: 22202497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
    Harder Yv
    Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
    [No Abstract]   [Full Text] [Related]  

  • 13. [Without short acting insulin analogs. Is therapy quality really maintained? (interview by Dirk Einecke)].
    Lüddeke HJ
    MMW Fortschr Med; 2006 Sep; 148(37):9. PubMed ID: 17036893
    [No Abstract]   [Full Text] [Related]  

  • 14. [Insulin aspart].
    Namba M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():492-7. PubMed ID: 12387040
    [No Abstract]   [Full Text] [Related]  

  • 15. [Human insulin vs. analogs. What is the cost of supplementary insulin therapy?].
    Lundershausen R; Potthoff F; Häuser C; Kaiser M; Münscher C
    MMW Fortschr Med; 2006 Nov; 148(45):42. PubMed ID: 17615748
    [No Abstract]   [Full Text] [Related]  

  • 16. [Conversation with Federal Health Administrator Ulla Schmidt. Physician payment will increase by about 4 billion (interview by Wolfgang van den Bergh and Bulent Erdogan)].
    Schmidt U
    MMW Fortschr Med; 2009 Jul; 151(30-33):8-9. PubMed ID: 19722450
    [No Abstract]   [Full Text] [Related]  

  • 17. [Insulin analogues--which dimension should be discussed?].
    Verspohl EJ
    Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
    [No Abstract]   [Full Text] [Related]  

  • 18. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long acting insulin analogues: results of clinical studies with insulin glargine].
    Fritsche A
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S101-5; discussion S124-6. PubMed ID: 18686217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Human Factor: The Cost of Switching from Analog to Human Insulin.
    Tsai A
    Diabetes Forecast; 2017 Mar; 70(2):44-47. PubMed ID: 29897684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.